Tag «vaccine»

Sinovac COVID-19 vaccine, CoronaVac,

It’s only fair to share… Sinovac COVID-19 vaccine, CoronaVac, PiCoVacc CoronaVac, also known as the Sinovac COVID-19 vaccine,[1] is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.[2] It has been in Phase III clinical trials in Brazil,[3] Chile,[4] Indonesia,[5] the Philippines,[6] and Turkey.[7] It relies on traditional technology similar to BBIBP-CorV and BBV152, other inactivated-virus COVID-19 vaccines in Phase III trials.[8] CoronaVac does not need to be frozen, and both the …

Johnson & Johnson COVID-19 vaccine, JNJ 78436735

It’s only fair to share… Johnson & Johnson COVID-19 vaccine, JNJ 78436735 Ad26.COV2.S JNJ-78436735 Ad26COVS1 VAC31518  UNII: JT2NS6183B https://www.onesourcedocs.com/wp-content/uploads/2021/03/Janssen_Pharmaceuticals_SDS_Ad26COVS1_100000015774_v3_5_202102_nr-1.pdf NAME DOSAGE STRENGTH ROUTE LABELLER MARKETING START MARKETING END Covid-19 Vaccine Janssen Injection, suspension 0.95 Inf. U Intramuscular Janssen Cilag International Nv 2021-03-17 Not applicable Janssen COVID-19 Vaccine Injection, suspension 50000000000 {VP}/0.5mL Intramuscular Janssen Products, LP …

NOVAWAX, NVX-CoV2373,

It’s only fair to share… NOVAWAX NVX-CoV2373 SARS-CoV-2 rS Nanoparticle Vaccine MCDC OTA agreement number W15QKN-16-9-1002 Novavax COVID-19 vaccine, Coronavirus disease 19 infection SARS-CoV-2 rS,  TAK 019 Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it had an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal …

BBIBP-CorV, Sinopharm COVID-19 vaccine

It’s only fair to share… BBIBP-CorV, Sinopharm COVID-19 vaccine CAS Number 2503126-65-4 Inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) Purified inactivated SARS-CoV-2 Vaccine ref Lancet Infectious Diseases (2021), 21(1), 39-51. BBIBP-CorV, also known as the Sinopharm COVID-19 vaccine,[1] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. In late December 2020, it was in Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 …

First FDA-approved vaccine Dengvaxia for the prevention of dengue disease in endemic regions

It’s only fair to share… First FDA-approved vaccine for the prevention of dengue disease in endemic regions May 01, 2019 The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people …